Study Details
Full Title
CL1-95032-005: A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Glioma
Principal Investigator
Katherine
Peters
Protocol Number
PRO00111363
NCT ID
NCT05484622
Phase
I
Enrollment Status
Open to Enrollment